BETA: Please send your feedback!
Wave Life Sciences
WVE:NAS
Biotechnology
$731.56mm
SMALL cap
$21.34
(-0.43%)
-0.50%
since start of 2019
-4.14
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- 1
-
CF
-
PP
-
WC
-
DP
-
CH
-
ES
-
WS
-
CG
-
EP
-
CM
-
FL
-
GD
- —
- 1
- 2
- 3
- 4
- 5
About
Biotechnology
Founded 2007
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company. It is focused on the discovery and development of treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases using its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James C. Jenson and John J. Rossi in 2007 and is headquartered in Watertown, MA.
website
Headquarters
Executives
| Name | Title | Gender |
| Gregory L. Verdine, PhD | Chairman | Male |
| Paul B. Bolno, MD, MBA | President, Chief Executive Officer & Director | Male |
| Keith Regnante, MBA | Chief Financial Officer | Male |
| Linda K. Rockett | General Counsel | Female |
| Takeshi Wada | Founder | Male |
| Peter Lasky | Chief Human Resources Officer & Senior VP | Male |
Mindful Investing Summary
- —
- 1
- 2
- 3
- 4
- 5
-
Carbon Footprint — N/A
-
Pollution Prevention — N/A
-
Water Conservation — N/A
-
Data & Privacy Protection — N/A
-
Consumer Health, Wellness & Safety — N/A
-
Employee Ownership, Satisfaction, Benefits & Pay — N/A
-
Workplace Health and Safety — N/A
-
Integrity of Corporate Governance — N/A
-
Ethical Practices — N/A
-
Usage of Conflict Materials — N/A
-
Forced Labor — N/A
-
Diversity of Corporate Leadership 1
Dicerna Pharmaceuticals - Competitors and Related Companies
How Dicerna Pharmaceuticals stacks up to its peers in the Biotechnology industry or with competing business segments.
Dicerna Pharmaceuticals
DRNA:NAS
Biotechnology
$872.96mm
SMALL cap
$12.77
(-0.28%)
0.06%
since start of 2019
-9.30
Loading…